Ophthalmology Innovation Summit
WHO: Vicken Karageozian, M.D., Co-Founder and Chief Technical Officer, Allegro Ophthalmics, will present “Allegro Ophthalmics: Accelerated Innovation, Needed Intervention” at the 5th annual Ophthalmology Innovation Summit (OIS).
WHAT: Dr. Karageozian will share insights into Allegro’s unique approach to accelerating medical research and commercialization of a new class of therapeutic drugs for vascular and vitreoretinal eye diseases, and will discuss ALG-1001 Integrin Peptide Therapy, including findings to date from human clinical studies in DME and Wet AMD.
WHEN: Thursday, November 14, 2013, 10:38-10:46 AM
WHERE: Sheraton New Orleans
2013 American Academy of Ophthalmology (AAO) Meeting
WHO: David Boyer, M.D., Founder, Retina-Vitreous Associates Medical Group, will present “Integrin Peptide Therapy: The First Human Wet AMD Experience” at the 2013 American Academy of Ophthalmology (AAO) meeting.
WHAT: Dr. Boyer will present findings to date from human clinical studies of ALG-1001 Integrin Peptide Therapy in Wet AMD.
WHEN: Tuesday, November 19, 2013, 10:12-10:19 AM
WHERE: Ernest N. Morial Convention Center, New Orleans, Room 271-273
ABOUT ALLEGRO OPHTHALMICS, LLC:
With more than 100 years of combined experience in ophthalmic drug discovery, development and manufacturing, Allegro Ophthalmics, LLC is establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic macular edema and vitreomacular traction, which together affect more than six million people in the US. By quickly, safely and cost-effectively bringing to market new and improved treatment options for these leading causes of blindness, Allegro is committed to offering patients an improved quality of life sustained by self-sufficient, functional vision. For more information, visit stg.allegroeye.com.
